Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Sage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

Sage Therapeutics (SAGE) PT Lowered to $48 at RBC Capital

November 2, 2021 1:54 PM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Sage Therapeutics (NASDAQ: SAGE) to $48.00 (from $52.00) while maintaining a Sector Perform rating.

Abrahams said changes to the CORAL design should improve POS, but it was not a huge surprise and underscores the uncertainties of Zura's commercial profile.

... More

SAGE Therapeutics (SAGE) Misses Q3 EPS by 36c, Reports $1.8B of Cash on Hand

November 2, 2021 6:40 AM EDT

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($2.21), $0.36 worse than the analyst estimate of ($1.85). Revenue for the quarter came in at $1.44 million versus the consensus estimate of $1.96 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

... More